Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 Shares of Stock

Posted by George Bondi on Jun 25th, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the sale, the chief operating officer owned 62,371 shares in the company, valued at $1,247,420. The trade was a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jennifer Champoux also recently made the following trade(s):

On Wednesday, June 17th, Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00.
On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Stock Up 3.9%

Shares of NASDAQ GLUE traded up $0.81 during trading hours on Thursday, hitting $21.66. The company had a trading volume of 1,768,259 shares, compared to its average volume of 1,328,242. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The firm’s 50 day moving average is $18.79 and its 200-day moving average is $18.58. The stock has a market capitalization of $1.83 billion, a P/E ratio of -14.64 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. On average, sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on GLUE. JPMorgan Chase & Co. upped their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Guggenheim dropped their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Read Our Latest Analysis on GLUE

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after acquiring an additional 257,547 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $778,000. Strs Ohio acquired a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth $566,000. CWM LLC raised its holdings in shares of Monte Rosa Therapeutics by 13.6% during the 4th quarter. CWM LLC now owns 29,444 shares of the company’s stock worth $462,000 after buying an additional 3,536 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after buying an additional 776 shares during the last quarter. Institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.